If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or fluffy solid |
| Water solubility | High | Dissolves in water and neutral buffers |
| Dry storage | -20 °C or below | Dry, dark, desiccated |
| Reconstituted storage | Frozen, single thaw | Repeated freeze-thaw promotes loss |
| Purity method | Reverse-phase HPLC | Peak area read at 214 or 220 nm |
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
== Ecology and behavior == American kestrels are found in a wide variety of habitats, including grasslands, meadows, deserts and other open to semi-open regions. They can also be found in both urban and suburban areas. A kestrel's habitat must include perches, open space for hunting, and cavities for nesting (whether natural or man-made). The American kestrel is able to live in very diverse conditions, ranging from above the Arctic Circle, to the tropics of Central America, to elevations of over 4,500 m (14,800 ft) in the Andes Mountains. The bird is distributed from northern Canada and Alaska to the southernmost tip of South America, Tierra del Fuego. It is the only kestrel found in the Americas, though as mentioned above this classification is genetically inaccurate. It has occurred as a vagrant in the UK, Denmark, Malta and the Azores.
January 19 – March 25: 2018 FIBA Americas League San Lorenzo defeated Mogi das Cruzes, 79–71, to win their first FIBA Americas League title. Regatas Corrientes took third place. June 11 – 16: 2018 FIBA Under-18 Americas Championship in St. Catharines The United States defeated Canada, 113–74, to win their fifth consecutive and ninth overall FIBA Under-18 Americas Championship title. Argentina took third place. August 1 – 7: 2018 FIBA Under-18 Women's Americas Championship in Mexico City The United States defeated Canada, 84–60, to win their ninth consecutive and tenth overall FIBA Under-18 Women's Americas Championship title. Argentina took third place.
Smith was hired to become the defensive quality control coach for the Tennessee Titans in 2011 under new head coach Mike Munchak. Smith then became the offensive quality coach the following season. In 2013, Smith was promoted to the assistant offensive line and assistant tight ends coach. Munchak was fired after the 2013 season and new head coach Ken Whisenhunt retained Smith as the assistant tight ends coach. Midway through the 2015 season, Whisenhunt was fired and replaced by tight ends coach Mike Mularkey. Mularkey was kept as head coach for the 2016 season and Smith was promoted to the new tight ends coach. When Mularkey was fired after the 2017 season, new head coach Mike Vrabel kept Smith as the tight ends coach for 2018. On January 21, 2019, Smith was promoted to offensive coordinator, replacing Matt LaFleur, who departed to become head coach of the Green Bay Packers two weeks prior. In his first year as offensive coordinator, Smith oversaw the highest-scoring Titans team in 16 years, with Derrick Henry, Ryan Tannehill, and Jonnu Smith having career years. Smith was praised for his play-calling in the Titans' 28–12 road victory over the top-seeded Baltimore Ravens in the AFC Divisional Round. In 2020, the Titans ranked fourth in scoring and second in total yards.
In April 2011, elevated levels of caesium-137 were also being found in the environment after the Fukushima Daiichi nuclear disasters in Japan. In July 2011, meat from 11 cows shipped to Tokyo from Fukushima Prefecture was found to have 1530 to 3200 becquerels per kilogram of 137Cs, considerably exceeding the Japanese legal limit of 500 becquerels per kilogram at that time. In March 2013, a fish caught near the plant had a record 740,000 becquerels per kilogram of radioactive caesium, above the 100 becquerels per kilogram government limit. A 2013 paper in Scientific Reports found that for a forest site 50 kilometres (30 miles) from the stricken plant, 137Cs concentrations were high in leaf litter, fungi and detritivores, but low in herbivores. By the end of 2014, "Fukushima-derived radiocaesium had spread into the whole western North Pacific Ocean", transported by the North Pacific current from Japan to the Gulf of Alaska. It has been measured in the ocean surface layer down to 200 meters (660 feet) and south of the current area down to 400 m (1,300 ft). Caesium-137 is reported to be the major health concern in Fukushima. A number of techniques are being considered that will be able to strip out 80% to 95% of the caesium from contaminated soil and other materials efficiently and without destroying the organic material in the soil. These include hydrothermal blasting.
Sources: en.wikipedia.org
In January 2026, Thomas Crosbie, an American military expert working at the Royal Danish Defence College, said that any attempt to seize Greenland would constitute a criminal act, and that Denmark, with the backing of its allies, would have the legal right to arrest any Americans involved in such actions and prosecute them under Danish criminal law. Danish troops in Greenland are legally obligated to defend Danish territory under military law. Under a 1952 standing order, Danish troops are ordered to "immediately take up the fight without waiting for, or seeking orders" in "the event of an attack on Danish territory". The Danish government confirmed in January 2026 that the order remains in place and that Danish soldiers would shoot back if Greenland is attacked. The Ministry of Defence said Danish troops would immediately respond to an invasion of Greenland with force and the chairman of the Defence Committee, Rasmus Jarlov, said Denmark would invoke Article 5 if attacked by the US. Jarlov said an American attack would mean war with Denmark and that retaliation would include deadly force. As of January 2026, Article 5 has been invoked only once in NATO history: in response to the September 11 attacks on the US in 2001, when Denmark volunteered "to fight alongside American soldiers in two different conflicts ... [deploying] tens of thousands of troops to Afghanistan and Iraq over two decades ... [suffering] the third-highest per capita casualty rate".
After neutrophils have finished phagocytosing and clearing the antigen at the end of the immune response, they undergo apoptosis, and macrophages are recruited from blood monocytes to help clear apoptotic debris. Macrophages also recruit other immune cells such as monocytes, dendritic cells, natural killer cells, basophils, eosinophils, and T cells through chemokines such as CCL2, CCL4, CCL5, CXCL8, CXCL9, CXCL10, and CXCL11. Along with dendritic cells, macrophages help activate natural killer (NK) cells through secretion of type I interferons (IFN-α and IFN-β) and IL-12. IL-12 acts with IL-18 to stimulate the production of proinflammatory cytokine interferon gamma (IFN-γ) by NK cells, which serves as an important source of IFN-γ before the adaptive immune system is activated. IFN-γ enhances the innate immune response by inducing a more aggressive phenotype in macrophages, allowing macrophages to more efficiently kill pathogens. Some of the T cell chemoattractants secreted by macrophages include CCL5, CXCL9, CXCL10, and CXCL11.
== Mechanism of action == Ptaquiloside has unstable chemical structure and readily undergoes glucose liberation. The resulting ptaquilodienone is the active form of ptaquiloside and accounts for the observed biological effects. The cyclopropyl group in the dienone is highly reactive as an electrophile, not only because it is conjugated with the keto group, but because it also constitutes a cyclopropyl carbinol system, from which the facile formation of the stable non-classical cation is well-known.
Sources: en.wikipedia.org
The data is from the year ending January 2, and market value is from March 11, 2011. In 2014, the chain was purchased by a foreign company, Brazilian firm 3G Capital, known for its ownership of Burger King. Despite foreign ownership, Tim Hortons remains a Canadian cultural phenomenon.
==== Camphor-alcohol treatment ==== Camphor treatment is similar to the alcohol-ether treatment but instead of a quick evaporation of the alcohol inside of the cells, the camphor alcohol slowly replaces cell walls with camphor which goes from a solid to a gas state over time, keeping walls of cells bulked. As a volatile solvent treatment option, the impact on the health and safety on the workplace must be considered.
=== EC 2.7.1: Phosphotransferases with an alcohol group as acceptor === EC 2.7.1.1: hexokinase EC 2.7.1.2: glucokinase EC 2.7.1.3: ketohexokinase EC 2.7.1.4: fructokinase EC 2.7.1.5: rhamnulokinase EC 2.7.1.6: galactokinase EC 2.7.1.7: mannokinase EC 2.7.1.8: glucosamine kinase EC 2.7.1.9: deleted EC 2.7.1.10: phosphoglucokinase EC 2.7.1.11: 6-phosphofructokinase EC 2.7.1.12: gluconokinase EC 2.7.1.13: dehydrogluconokinase EC 2.7.1.14: sedoheptulokinase EC 2.7.1.15: ribokinase EC 2.7.1.16: ribulokinase EC 2.7.1.17: xylulokinase EC 2.7.1.18: phosphoribokinase EC 2.7.1.19: phosphoribulokinase EC 2.7.1.20: adenosine kinase EC 2.7.1.21: thymidine kinase EC 2.7.1.22: ribosylnicotinamide kinase EC 2.7.1.23: NAD+ kinase EC 2.7.1.24: dephospho-CoA kinase EC 2.7.1.25: adenylyl-sulfate kinase EC 2.7.1.26: riboflavin kinase EC 2.7.1.27: erythritol kinase (D-erythritol 4-phosphate-forming) EC 2.7.1.28: triokinase EC 2.7.1.29: glycerone kinase EC 2.7.1.30: glycerol kinase EC 2.7.1.31: glycerate kinase EC 2.7.1.32: choline kinase EC 2.7.1.33: pantothenate kinase EC 2.7.1.34: pantetheine kinase EC 2.7.1.35: pyridoxal kinase EC 2.7.1.36: mevalonate kinase EC 2.7.1.37: now divided into EC 2.7.11.1, EC 2.7.11.8, EC 2.7.11.9, EC 2.7.11.10, EC 2.7.11.11, EC 2.7.11.12, EC 2.7.11.13, EC 2.7.11.21, EC 2.7.11.22, EC 2.7.11.24, EC 2.7.11.25, EC 2.7.11.30 and EC 2.7.12.1 EC 2.7.1.38: now EC 2.7.11.19, phosphorylase kinase EC 2.7.1.39: homoserine kinase EC 2.7.1.40: pyruvate kinase EC 2.7.1.41: glucose-1-phosphate phosphodismutase EC 2.7.1.42: riboflavin phosphotransferase EC 2.7.1.43: glucuronokinase EC 2.7.1.44: galacturonokinase EC 2.7.1.45: 2-dehydro-3-deoxygluconokinase EC 2.7.1.46: L-arabinokinase EC 2.7.1.47: D-ribulokinase EC 2.7.1.48: uridine kinase EC 2.7.1.49: hydroxymethylpyrimidine kinase EC 2.7.1.50: hydroxyethylthiazole kinase EC 2.7.1.51: L-fuculokinase EC 2.7.1.52: fucokinase EC 2.7.1.53: L-xylulokinase EC 2.7.1.54: D-arabinokinase EC 2.7.1.55: allose kinase EC 2.7.1.56: 1-phosphofructokinase EC 2.7.1.57: deleted EC 2.7.1.58: 2-dehydro-3-deoxygalactonokinase EC 2.7.1.59: N-acetylglucosamine kinase EC 2.7.1.60: N-acylmannosamine kinase EC 2.7.1.61: acyl-phosphate—hexose phosphotransferase EC 2.7.1.62: Phosphoramidate-hexose phosphotransferase EC 2.7.1.63: polyphosphate—glucose phosphotransferase EC 2.7.1.64: inositol 3-kinase EC 2.7.1.65: scyllo-inosamine 4-kinase EC 2.7.1.66: undecaprenol kinase EC 2.7.1.67: 1-phosphatidylinositol 4-kinase EC 2.7.1.68: 1-phosphatidylinositol-4-phosphate 5-kinase EC 2.7.1.69: now covered by EC 2.7.1.191, EC 2.7.1.192, EC 2.7.1.193, EC 2.7.1.194, EC 2.7.1.195, EC 2.7.1.196, EC 2.7.1.197, EC 2.7.1.198, EC 2.7.1.199, EC 2.7.1.200 EC 2.7.1.20, EC 2.7.1.202, EC 2.7.1.203, EC 2.7.1.204, EC 2.7.1.205, EC 2.7.1.206, EC 2.7.1.207 and EC 2.7.1.208 EC 2.7.1.70: Now included in EC 2.7.11.1, non-specific serine/threonine protein kinase EC 2.7.1.71: shikimate kinase EC 2.7.1.72: streptomycin 6-kinase EC 2.7.1.73: inosine kinase EC 2.7.1.74: deoxycytidine kinase EC 2.7.1.75: Now EC 2.7.1.21 thymidine kinase EC 2.7.1.76: deoxyadenosine kinase EC 2.7.1.77: nucleoside phosphotransferase EC 2.7.1.78: polynucleotide 5′-hydroxyl-kinase EC 2.7.1.79: diphosphate—glycerol phosphotransferase EC 2.7.1.80: diphosphate—serine phosphotransferase EC 2.7.1.81: hydroxylysine kinase EC 2.7.1.82: ethanolamine kinase EC 2.7.1.83: pseudouridine kinase EC 2.7.1.84: alkylglycerone kinase EC 2.7.1.85: β-glucoside kinase EC 2.7.1.86: NADH kinase EC 2.7.1.87: streptomycin 3′′-kinase EC 2.7.1.88: dihydrostreptomycin-6-phosphate 3′α-kinase EC 2.7.1.89: thiamine kinase EC 2.7.1.90: diphosphate—fructose-6-phosphate 1-phosphotransferase EC 2.7.1.91: sphinganine kinase EC 2.7.1.92: 5-dehydro-2-deoxygluconokinase EC 2.7.1.93: alkylglycerol kinase EC 2.7.1.94: acylglycerol kinase EC 2.7.1.95: kanamycin kinase EC 2.7.1.96: deleted, Now included with EC 2.7.1.86 NADH kinase EC 2.7.1.97: deleted, Identical with EC 2.7.11.14, rhodopsin kinase EC 2.7.1.98: deleted EC 2.7.1.99: Now EC 2.7.11.2, [pyruvate dehydrogenase (acetyl-transferring)] kinase EC 2.7.1.100: S-methyl-5-thioribose kinase EC 2.7.1.101: tagatose kinase EC 2.7.1.102: hamamelose kinase EC 2.7.1.103: viomycin kinase EC 2.7.1.104: Now EC 2.7.99.1, triphosphate—protein phosphotransferase EC 2.7.1.105: 6-phosphofructo-2-kinase EC 2.7.1.106: glucose-1,6-bisphosphate synthase EC 2.7.1.107: diacylglycerol kinase EC 2.7.1.108: dolichol kinase EC 2.7.1.109: Now EC 2.7.11.31, [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase EC 2.7.1.110: Now EC 2.7.11.3, dephospho-(reductase kinase) kinase EC 2.7.1.111: Now listed as EC 2.7.11.27, [acetyl-CoA carboxylase] kinase EC 2.7.1.112: Now EC 2.7.10.2, non-specific protein-tyrosine kinase EC 2.7.1.113: deoxyguanosine kinase EC 2.7.1.114: AMP—thymidine kinase EC 2.7.1.115: Now EC 2.7.11.4, (3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)) kinase EC 2.7.1.116: Now EC 2.7.11.5, [isocitrate dehydrogenase (NADP+)] kinase EC 2.7.1.117: Now EC 2.7.11.18, myosin-light-chain kinase EC 2.7.1.118: ADP—thymidine kinase EC 2.7.1.119: hygromycin-B 7′′-O-kinase EC 2.7.1.120: Now EC 2.7.11.17, Ca2+/calmodulin-dependent protein kinase EC 2.7.1.121: phosphoenolpyruvate—glycerone phosphotransferase EC 2.7.1.122: xylitol kinase EC 2.7.1.123: Now EC 2.7.11.17, Ca2+/calmodulin-dependent protein kinase EC 2.7.1.124: Now EC 2.7.11.6, [tyrosine 3-monooxygenase] kinase EC 2.7.1.125: Now EC 2.7.11.14, rhodopsin kinase EC 2.7.1.126: Now EC 2.7.11.15, β-adrenergic-receptor kinase EC 2.7.1.127: inositol-trisphosphate 3-kinase EC 2.7.1.128: Now EC 2.7.11.27, [acetyl-CoA carboxylase] kinase EC 2.7.1.129: Now EC 2.7.11.7, myosin-heavy-chain kinase EC 2.7.1.130: tetraacyldisaccharide 4′-kinase EC 2.7.1.131: Now EC 2.7.11.29, low-density-lipoprotein receptor kinase EC 2.7.1.132: Now EC 2.7.11.28, tropomyosin kinase EC 2.7.1.133: Now included with EC 2.7.1.134, inositol-tetrakisphosphate 1-kinase EC 2.7.1.134: inositol-tetrakisphosphate 1-kinase EC 2.7.1.135: Now EC 2.7.11.26, tau-protein kinase EC 2.7.1.136: macrolide 2′-kinase EC 2.7.1.137: phosphatidylinositol 3-kinase EC 2.7.1.138: ceramide kinase EC 2.7.1.139: Now included with EC 2.7.1.134, inositol-tetrakisphosphate 1-kinase EC 2.7.1.140: inositol-tetrakisphosphate 5-kinase EC 2.7.1.141: Now EC 2.7.11.23, [RNA-polymerase]-subunit kinase EC 2.7.1.142: glycerol-3-phosphate—glucose phosphotransferase EC 2.7.1.143: diphosphate-purine nucleoside kinase EC 2.7.1.144: tagatose-6-phosphate kinase EC 2.7.1.145: deoxynucleoside kinase EC 2.7.1.146: ADP-dependent phosphofructokinase EC 2.7.1.147: ADP-dependent glucokinase EC 2.7.1.148: 4-(cytidine 5′-diphospho)-2-C-methyl-D-erythritol kinase EC 2.7.1.149: 1-phosphatidylinositol-5-phosphate 4-kinase EC 2.7.1.150: 1-phosphatidylinositol-3-phosphate 5-kinase EC 2.7.1.151: inositol-polyphosphate multikinase EC 2.7.1.152: Now EC 2.7.4.21, inositol-hexakisphosphate kinase EC 2.7.1.153: phosphatidylinositol-4,5-bisphosphate 3-kinase EC 2.7.1.154: phosphatidylinositol-4-phosphate 3-kinase EC 2.7.1.155: Now EC 2.7.4.24, diphosphoinositol-pentakisphosphate kinase EC 2.7.1.156: adenosylcobinamide kinase EC 2.7.1.157: N-acetylgalactosamine kinase EC 2.7.1.158: inositol-pentakisphosphate 2-kinase EC 2.7.1.159: inositol-1,3,4-trisphosphate 5/6-kinase EC 2.7.1.160: 2′-phosphotransferase EC 2.7.1.161: CTP-dependent riboflavin kinase EC 2.7.1.162: N-acetylhexosamine 1-kinase EC 2.7.1.163: hygromycin B 4-O-kinase EC 2.7.1.164: O-phosphoseryl-tRNASec kinase EC 2.7.1.165: glycerate 2-kinase EC 2.7.1.166: 3-deoxy-D-manno-octulosonic acid kinase EC 2.7.1.167: D-glycero-β-D-manno-heptose-7-phosphate kinase EC 2.7.1.168: D-glycero-α-D-manno-heptose-7-phosphate kinase EC 2.7.1.169: pantoate kinase EC 2.7.1.170: anhydro-N-acetylmuramic acid kinase EC 2.7.1.171: protein-fructosamine 3-kinase EC 2.7.1.172: protein-ribulosamine 3-kinase EC 2.7.1.173: nicotinate riboside kinase EC 2.7.1.174: diacylglycerol kinase (CTP dependent) EC 2.7.1.175: maltokinase EC 2.7.1.176: UDP-N-acetylglucosamine kinase EC 2.7.1.177: L-threonine kinase EC 2.7.1.178: 2-dehydro-3-deoxyglucono/galactono-kinase EC 2.7.1.179: kanosamine kinase EC 2.7.1.180: FAD:protein FMN transferase EC 2.7.1.181: polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol kinase EC 2.7.1.182: phytol kinase EC 2.7.1.183: glycoprotein-mannosyl O6-kinase EC 2.7.1.184: sulfofructose kinase EC 2.7.1.185: mevalonate 3-kinase EC 2.7.1.186: mevalonate-3-phosphate 5-kinase EC 2.7.1.187: acarbose 7IV-phosphotransferase EC 2.7.1.188: 2-epi-5-epi-valiolone 7-kinase EC 2.7.1.189: autoinducer-2 kinase EC 2.7.1.190: aminoglycoside 2′′-phosphotransferase EC 2.7.1.191: protein-N π-phosphohistidine—D-mannose phosphotransferase EC 2.7.1.192: protein-N π-phosphohistidine—N-acetylmuramate phosphotransferase EC 2.7.1.193: protein-N π-phosphohistidine—N-acetyl-D-glucosamine phosphotransferase EC 2.7.1.194: protein-N π-phosphohistidine—L-ascorbate phosphotransferase EC 2.7.1.195: protein-N π-phosphohistidine—2-O-α-mannosyl-D-glycerate phosphotransferase EC 2.7.1.196: protein-N π-phosphohistidine—N,N′-diacetylchitobiose phosphotransferase EC 2.7.1.197: protein-Nπ'-phosphohistidine—D-mannitol phosphotransferase EC 2.7.1.198: protein-N π-phosphohistidine—D-sorbitol phosphotransferase EC 2.7.1.199: protein-N π-phosphohistidine—D-glucose phosphotransferase EC 2.7.1.200: protein-N π-phosphohistidine—galactitol phosphotransferase EC 2.7.1.201: protein-N π-phosphohistidine—trehalose phosphotransferase EC 2.7.1.202: protein-N π-phosphohistidine—D-fructose phosphotransferase EC 2.7.1.203: protein-N π-phosphohistidine—D-glucosaminate phosphotransferase EC 2.7.1.204: protein-N π-phosphohistidine—D-galactose phosphotransferase EC 2.7.1.205: protein-N π-phosphohistidine—cellobiose phosphotransferase EC 2.7.1.206: protein-N π-phosphohistidine—L-sorbose phosphotransferase EC 2.7.1.207: protein-N π-phosphohistidine—lactose phosphotransferase EC 2.7.1.208: protein-N π-phosphohistidine—maltose phosphotransferase EC 2.7.1.209: L-erythrulose 1-kinase EC 2.7.1.210: D-erythrulose 4-kinase EC 2.7.1.211: protein-N π-phosphohistidine—sucrose phosphotransferase EC 2.7.1.212: α-D-ribose-1-phosphate 5-kinase (ADP) EC 2.7.1.213: cytidine kinase EC 2.7.1.214: C7-cyclitol 7-kinase EC 2.7.1.215: erythritol kinase (D-erythritol 1-phosphate-forming) EC 2.7.1.216: farnesol kinase EC 2.7.1.217: 3-dehydrotetronate 4-kinase EC 2.7.1.218: fructoselysine 6-kinase EC 2.7.1.219: D-threonate 4-kinase EC 2.7.1.220: D-erythronate 4-kinase EC 2.7.1.221: N-acetylmuramate 1-kinase EC 2.7.1.222: 4-hydroxytryptamine kinase EC 2.7.1.223: aminoimidazole riboside kinase EC 2.7.1.224: cytidine diphosphoramidate kinase EC 2.7.1.225: L-serine kinase (ATP) EC 2.7.1.226: L-serine kinase (ADP) EC 2.7.1.227: inositol phosphorylceramide synthase EC 2.7.1.228: mannosyl-inositol-phosphoceramide inositolphosphotransferase EC 2.7.1.229: deoxyribokinase EC 2.7.1.230: amicoumacin kinase EC 2.7.1.231: 3-oxoisoapionate kinase EC 2.7.1.232: levoglucosan kinase EC 2.7.1.233: apulose kinase
Sources: en.wikipedia.org
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.
Suppliers typically quote a percentage derived from reverse-phase HPLC peak area. That figure reflects the relative amount of the main peak and does not by itself confirm identity or exclude related impurities. Mass spectrometry is commonly paired with it for confirmation.
Peptides purified by reverse-phase chromatography often carry trifluoroacetate as a counter-ion, which adds mass and can affect solubility and apparent behavior in assays. Acetate and hydrochloride forms are also offered. Knowing which form is present matters when calculating how much peptide a given weight contains.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.